Payment overview · 2025
General Payments
$410.34
23 reported records · 12 companies
Healthcare provider profile · identity verified
Randall Hearne, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PERRY, FL · NPI 1831184910
Verified facts
What the public records show
CMS Open Payments records show Randall Hearne, ARNP received $410.34 in general payments during 2025 across 23 reported records.
Lilly USA, LLC accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta, Trintellix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.71 | 26.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.24 | 15.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.65 | 12.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.65 | 11.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.69 | 7.2% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.05 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.40 | 5.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.66 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.91 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.32 | 3.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.06 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.00 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $410.34 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.71 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.71 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.24 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.65 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.69 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 364 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 85 |
| Gabapentin | Gabapentin | 240 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 60 |
| Metformin Hcl | Metformin Hcl | 192 | 55 |
| Lisinopril | Lisinopril | 189 | 55 |
| Losartan Potassium | Losartan Potassium | 172 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 48 |
| Furosemide | Furosemide | 154 | 56 |
| Methylprednisolone | Methylprednisolone | 149 | 111 |
| Potassium Chloride | Potassium Chloride | 148 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 51 |
| Carvedilol | Carvedilol | 117 | 33 |
| Meloxicam | Meloxicam | 116 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 28 |
| Simvastatin | Simvastatin | 111 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 24 |
| Montelukast Sodium | Montelukast Sodium | 99 | 33 |
| Trazodone Hcl | Trazodone Hcl | 99 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 31 |
| Famotidine | Famotidine | 89 | 25 |
| Azithromycin | Azithromycin | 86 | 77 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 24 |
| Bupropion Xl | Bupropion Hcl | 80 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 24 |
| Allopurinol | Allopurinol | 75 | 25 |
| Glimepiride | Glimepiride | 74 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 24 |
| Spironolactone | Spironolactone | 72 | 17 |
| Eliquis | Apixaban | 65 | 17 |
| Metformin Hcl Er | Metformin Hcl | 62 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 17 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 17 |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Fenofibrate | Fenofibrate | 55 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 22 |
| Prednisone | Prednisone | 53 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 22 |
| Celecoxib | Celecoxib | 47 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 14 |
| Atenolol | Atenolol | 45 | 11 |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Finasteride | Finasteride | 42 | suppressed |
| Glipizide Er | Glipizide | 42 | 15 |
| Ibuprofen | Ibuprofen | 41 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | 18 |
| Baclofen | Baclofen | 40 | 17 |
| Clonidine Hcl | Clonidine Hcl | 40 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 36 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Jardiance | Empagliflozin | 38 | 11 |
| Sucralfate | Sucralfate | 38 | 20 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 14 |
| Promethazine Hcl | Promethazine Hcl | 37 | 16 |
| Topiramate | Topiramate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Ozempic | Semaglutide | 34 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 31 |
| Irbesartan | Irbesartan | 31 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Valsartan | Valsartan | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | 11 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 26 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 14 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Minoxidil | Minoxidil | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Sulindac | Sulindac | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $410.34 · 23 records | Lilly USA, LLC | ABRYSVO, AREXVY, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, Jornay PM, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, Qelbree, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error